COVID-19 outcomes in UK centre within highest health and wealth band: a prospective cohort study.
COVID-19
epidemiology
public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
16 11 2020
16 11 2020
Historique:
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
15
12
2020
Statut:
epublish
Résumé
To describe the characteristics and outcomes of hospitalised patients with COVID-19 from UK in the highest decile of health and gross regional products per capita. Prospective cohort study. Recruited all adult inpatients with laboratory-confirmed COVID-19 symptoms admitted to a single Surrey centre between March and April 2020. Extensive demographic details were documented. COVID-19 status of alive/dead and intensive care unit (ICU) status of yes/no. Patients with COVID-19 from Surrey centre UK (n=429). 429 adult inpatients (mean age 70±18 years; men 56.4%) were included in this study, of whom, 19.1% required admission to ICU and 31.9% died. Adverse outcomes were associated with age (OR with each decade of years: 1.78, 95% CI 1.53 to 2.11, p<0.001 for mortality); male gender (OR=1.08, 95% CI 0.72 to 1.63, p=0.72, present in 70.7%, of admissions to ICU versus 53% of other cases, p=0.004); cardiac disease (OR=3.43, 95% CI 2.10 to 5.63, p<0.001), diabetes mellitus (OR=2.37, 95% CI 1.09 to 5.17, p=0.028) and dementia (OR=5.06, 95% CI 2.79 to 9.44, p<0.001). There was no significant impact of ethnicity or body mass index on disease outcome. Despite reports of worse outcomes in deprived regions, we show similar complication and mortality rates due to COVID-19 in an affluent and high life expectancy region.
Identifiants
pubmed: 33199428
pii: bmjopen-2020-042090
doi: 10.1136/bmjopen-2020-042090
pmc: PMC7670555
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e042090Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Infect Dis. 2020 Jul 28;71(15):706-712
pubmed: 32109279
Clin Microbiol Infect. 2020 Jul;26(7):948.e1-948.e3
pubmed: 32360780
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Acta Ophthalmol. 2020 May 18;:
pubmed: 32421258
JAMA. 2020 Jun 2;323(21):2192-2195
pubmed: 32347898
Lancet. 2020 Apr 18;395(10232):1243-1244
pubmed: 32305087
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
Lancet. 2020 May 2;395(10234):1421-1422
pubmed: 32330427
BMJ. 2020 Apr 20;369:m1548
pubmed: 32312785
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
Int J Environ Res Public Health. 2020 May 29;17(11):
pubmed: 32485854
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
BMC Infect Dis. 2020 Apr 29;20(1):311
pubmed: 32345226
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
J Infect. 2020 Aug;81(2):e59-e61
pubmed: 32353384
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
Int J Epidemiol. 2012 Feb;41(1):33-42
pubmed: 21044979
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9696-9698
pubmed: 32300018
J Formos Med Assoc. 2020 May;119(5):982-989
pubmed: 32307322
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Ann Epidemiol. 2020 Aug;48:9-14
pubmed: 32723697
J R Soc Med. 2015 Oct;108(10):406-17
pubmed: 26152675
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
BMJ. 2017 Feb 15;356:i6583
pubmed: 28202713
BMC Med. 2014 Apr 10;12:61
pubmed: 24722122